Spero Therapeutics Inc. (NASDAQ: SPRO)
$1.50
+0.0550 ( +3.81% ) 207.3K
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Market Data
Open
$1.50
Previous close
$1.45
Volume
207.3K
Market cap
$80.44M
Day range
$1.44 - $1.53
52 week range
$0.99 - $1.89
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
10-q | Quarterly Reports | 58 | May 15, 2024 |
ars | Annual reports | 1 | Apr 16, 2024 |
def | Proxies and info statements | 22 | Apr 16, 2024 |
8-k | 8K-related | 13 | Mar 29, 2024 |
10-k | Annual reports | 107 | Mar 13, 2024 |
8-k | 8K-related | 15 | Mar 13, 2024 |
8-k | 8K-related | 14 | Feb 09, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |
4 | Insider transactions | 1 | Feb 05, 2024 |